Ani Pharmaceuticals (ANIP) Other Non-Current Liabilities (2011 - 2026)

Ani Pharmaceuticals has reported Other Non-Current Liabilities for 13 years, with the latest figure at $8.6 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 22.51% year-over-year to $8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.6 million (up 22.51% YoY) and the FY2025 annual result came in at $12.2 million, up 110.41% from the prior year.
• Other Non-Current Liabilities eased to $8.6 million in Q1 2026 per ANIP's latest filing, from $12.2 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $32.1 million in Q1 2022 and troughed at $1.0 million in Q2 2022.
• A 5-year average of $8.4 million and a median of $6.7 million in 2025 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities tumbled 96.25% in 2023, then surged 828.45% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $1.4 million in 2022, then surged by 248.23% to $4.8 million in 2023, then rose by 20.21% to $5.8 million in 2024, then jumped by 110.41% to $12.2 million in 2025, then slipped by 29.3% to $8.6 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $8.6 million, $12.2 million, and $8.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.